Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Daiichi Sankyo enters merger agreement to acquire Plexxikon

Plexxikon Inc. today announced it has entered into a merger agreement with Daiichi Sankyo Company, Limited, a Japan-based global pharmaceutical company.

28 Feb 2011

Celgene's ISTODAX sNDA granted FDA Priority Review classification for progressive/relapsed PTCL

Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review classification to its Supplemental New Drug Application (sNDA) regarding ISTODAX (romidepsin) for injection for the treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy.

28 Feb 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.

28 Feb 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

New rapid and inexpensive test can effectively identify never-smoking group with lung adenocarcinoma

An inexpensive and rapid testing method can effectively identify a sub-group of never-smoking lung cancer patients whose tumors express a molecule associated with increased risk of disease progression or recurrence, US researchers have found.

25 Feb 2011

MD Anderson physician honored for impact on blood, marrow transplantation

The American Society for Blood and Marrow Transplantation has honored leader, innovator and educator Richard Champlin, M.D., with its Lifetime Achievement Award during the group's annual meeting Feb. 17-21.

23 Feb 2011

Cancer-causing retrovirus prolongs survival of host cells

A cancer-causing retrovirus exploits key proteins in its host cells to extend the life of those cells, thereby prolonging its own survival and ability to spread, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) and Ohio State's College of Veterinary Medicine.

23 Feb 2011

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.

22 Feb 2011

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Fate Therapeutics, Inc. presented encouraging preliminary data from an ongoing Phase 1b clinical trial of FT1050 at the 2011 BMT Tandem Meetings in Honolulu, Hawaii.

22 Feb 2011

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia patients resistant to current therapies. The company also announced promising non-clinical results in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of Acadra in combination with current treatment in these indications has been demonstrated.

21 Feb 2011

Loyola offers stem cell transplants to older patients with leukemia and lymphoma

As the first baby boomers turn 65, Loyola University Hospital has begun offering stem cell transplants to leukemia and lymphoma patients who previously were too old to qualify.

18 Feb 2011

Astellas' Protopic receives Health Canada approval for prevention of eczema flares

Astellas Pharma Canada, Inc. has announced that it has received approval from Health Canada for a new indication for its topical eczema therapy, Protopic® (tacrolimus ointment 0.03% and 0.1%). The new indication means that tacrolimus ointment can be prescribed for maintenance therapy to prevent flares and prolong flare free intervals in patients with moderate to severe atopic dermatitis (commonly called eczema).

17 Feb 2011

American Academy of Dermatology releases final guidelines of care for psoriasis

Building on the evidence-based findings of five previously published guidelines of care that examine the use of a variety of medical therapies for the management and treatment of psoriasis and psoriatic arthritis, the American Academy of Dermatology has released its sixth and final guidelines of care for psoriasis.

16 Feb 2011

CTI's fourth quarter net loss increases to $34.1 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2010.

16 Feb 2011

Combined chemotherapy and radiation therapy effective against Hodgkin's lymphoma, in the short term

Modern treatment for early stage Hodgkin's lymphoma is highly effective, leaving most patients with no evidence of cancer. However, experts differ on the best approach: Is chemotherapy enough or does adding radiation therapy improve the outcome?

16 Feb 2011

Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL

Halozyme Therapeutics, Inc. and Roche today announced the first patient received subcutaneous MabThera (rituximab), an anticancer biologic, in a Phase 3 registration trial using Enhanze technology.

16 Feb 2011

New algorithm guides plastic surgeons in managing women with ALCL after breast augmentation

In the wake of a recent FDA statement linking breast implants to a rare cancer called anaplastic large cell lymphoma, a newly updated algorithm provides plastic surgeons with guidance in managing women with breast lumps or swelling after breast augmentation.

15 Feb 2011

Screening breast MRIs can detect invasive cancers in women with history of chest irradiation

Breast cancer screening with MRI can detect invasive cancers missed on mammography in women who've undergone chest irradiation for other diseases, according to a new study published online and in the April print edition of Radiology.

15 Feb 2011

Neurologic and neurosurgical patients do not receive therapy to prevent VTE: Study

Patients with strokes, brain tumors and spinal cord injuries are at high risk for life-threatening blood clots, but many do not receive preventive therapy, Loyola University Health System researchers report.

14 Feb 2011

First patient treated in cytomegalovirus~ACE/ASPECT Phase II randomised clinical trial

Cell Medica, a leading UK cellular therapeutics company that develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, announces today that the first patient has been treated in the CMV~ACE/ASPECT trial at University College Hospital London.

10 Feb 2011

Lymphoma News and Research

Further Reading

Daiichi Sankyo enters merger agreement to acquire Plexxikon

Celgene's ISTODAX sNDA granted FDA Priority Review classification for progressive/relapsed PTCL

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

New rapid and inexpensive test can effectively identify never-smoking group with lung adenocarcinoma

MD Anderson physician honored for impact on blood, marrow transplantation

Cancer-causing retrovirus prolongs survival of host cells

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

Loyola offers stem cell transplants to older patients with leukemia and lymphoma

Astellas' Protopic receives Health Canada approval for prevention of eczema flares

American Academy of Dermatology releases final guidelines of care for psoriasis

CTI's fourth quarter net loss increases to $34.1 million

Combined chemotherapy and radiation therapy effective against Hodgkin's lymphoma, in the short term

Halozyme-Roche announce initiation of Phase 3 subcutaneous MabThera trial in follicular NHL

New algorithm guides plastic surgeons in managing women with ALCL after breast augmentation

Screening breast MRIs can detect invasive cancers in women with history of chest irradiation

Neurologic and neurosurgical patients do not receive therapy to prevent VTE: Study

First patient treated in cytomegalovirus~ACE/ASPECT Phase II randomised clinical trial

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News